Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Abaloparatide for treating osteoporosis in postmenopausal women have been revised. It is anticipated that the appraisal will begin in mid-July 2023 when we will write to you about how you can get involved.